The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
8 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $5,011,319 in first-year total cost, median $625,575.
Most frequent study sections
- Special Emphasis Panel[ZMH1 ERB-M (07)]8
Most frequent institutions
- YALE UNIVERSITY2
- CLEVELAND CLINIC LERNER COM-CWRU1
- MAYO CLINIC ROCHESTER1
- NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC1
- STANFORD UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2020 | Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine1R01MH125203-01 | DWYER, JENNIFER BUENZLE | YALE UNIVERSITY, CT | $669,965 | ZMH1 |
| 2020 | The Effects of Stanford Accelerated Intelligent Neuromodulation Therapy on Explicit and Implicit Suicidal Cognition1R01MH125160-01 | WILLIAMS, NOLAN R. | STANFORD UNIVERSITY, CA | $630,597 | ZMH1 |
| 2020 | A Randomized Controlled Trial of Sequential Bilateral Accelerated Theta Burst Stimulation in Adolescents with Suicidal Ideation Associated with Major Depressive Disorder1R01MH124655-01 | CROARKIN, PAUL E | MAYO CLINIC ROCHESTER, MN | $630,163 | ZMH1 |
| 2020 | Effectiveness of a Synergistic, Neuroplasticity-Based intervention for Rapid and Durable Suicide Risk Reduction1R01MH124983-01 | PRICE, REBECCA | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $626,853 | ZMH1 |
| 2020 | Ketamine Treatment of Youth Suicide Attempters for Fast Reduction of Severe Suicide Risk and Facilitation of Long-term Collaborative Clinical Engagement: A Randomized Placebo Controlled Trial1R01MH125214-01 | ANAND, AMITFALCONE, TATIANA | CLEVELAND CLINIC LERNER COM-CWRU, OH | $624,296 | ZMH1 |
| 2020 | Double-Blind Randomized Controlled Trial of Acute-Course of Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents1R01MH125181-01 | TRIVEDI, MADHUKAR H. | UT SOUTHWESTERN MEDICAL CENTER, TX | $620,262 | ZMH1 |
| 2020 | IM Ketamine for rapid reduction of suicidal thoughts in high-risk emergency room patients: a midazolam-controlled trial1R01MH125155-01 | GRUNEBAUM, MICHAEL F | NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC, NY | $607,024 | ZMH1 |
| 2020 | A feasibility trial of esketamine plus cognitive behavioral therapy for patients with major depressive disorder who are hospitalized for suicidal ideation1R01MH125205-01 | WILKINSON, SAMUEL | YALE UNIVERSITY, CT | $602,159 | ZMH1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.